Aging Frailty
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Fine-tuned Physical Training to Improve Quality of Life in Older Individuals
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
FAXAGE: Fasting And Exercise To Slow Aging In Humans
Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction
A Comparative Study of Subjects Past Their Final Follow-ON Visit
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty